Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
Drug results: 1
| ensitrelvir | Ensitrelvir is an orally active 3C-like protease inhibitor and it was approved for emergency use in Japan in November 2022. Ensitrelvir has reached Phase III clinical trials and is being evaluated for its efficacy and safety in patients with mild-to-moderate COVID-19. |
|








Citing DrugCentral © 2026.
License